Paper40580997
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.
Tsimberidou AM and 13 others. Oncologist, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. Papers, record 40580997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40580997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Jumonji Domain-Containing Histone Demethylases | Major topic |
| Humans | |
| Male | |
| Middle Aged | |
| Female | |
| Aged | |
| Adult | |
| Maximum Tolerated Dose |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| CLIN2-14232 | California Institute for Regenerative Medicine | PubMed | PubMed | ||
| University of Texas MD Anderson Cancer Center | PubMed | PubMed | |||
| Tachyon Therapeutics, Inc | PubMed | PubMed | |||
| NIH HHS | United States | PubMed | PubMed | ||
| R03AG014232 | NIH | NIH RePORTER |
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27266524 | Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. | EMBO J | 2016 | https://conductscience.org/library/papers/27266524 | PubMed |
| 2 | 25770186 | Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway. | Biol Open | 2015 | https://conductscience.org/library/papers/25770186 | PubMed |
| 3 | 23644528 | KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. | Cancer Res | 2013 | https://conductscience.org/library/papers/23644528 | PubMed |
| 4 | 27630312 | Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma. | Anticancer Res | 2016 | https://conductscience.org/library/papers/27630312 | PubMed |
| 5 | 30967636 | JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. | Oncogene | 2019 | https://conductscience.org/library/papers/30967636 | PubMed |
| 6 | 31766290 | Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31766290 | PubMed |
| 7 | 28883001 | KDM4 Inhibition Targets Breast Cancer Stem-like Cells. | Cancer Res | 2017 | https://conductscience.org/library/papers/28883001 | PubMed |
| 8 | 27506941 | KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/27506941 | PubMed |
| 9 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 10 | 17555712 | Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. | Biochem Biophys Res Commun | 2007 | https://conductscience.org/library/papers/17555712 | PubMed |
| 11 | 22948256 | Oncogenic features of the JMJD2A histone demethylase in breast cancer. | Int J Oncol | 2012 | https://conductscience.org/library/papers/22948256 | PubMed |
| 12 | 23603248 | Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. | Cancer Lett | 2013 | https://conductscience.org/library/papers/23603248 | PubMed |
| 13 | 28835804 | Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. | ACS Med Chem Lett | 2017 | https://conductscience.org/library/papers/28835804 | PubMed |
| 14 | 19696013 | The histone demethylase JMJD2C is stage-specifically expressed in preimplantation mouse embryos and is required for embryonic development. | Biol Reprod | 2010 | https://conductscience.org/library/papers/19696013 | PubMed |
| 15 | 17218267 | Dynamic regulation of histone lysine methylation by demethylases. | Mol Cell | 2007 | https://conductscience.org/library/papers/17218267 | PubMed |
| 16 | 33558705 | USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription. | Cell Death Differ | 2021 | https://conductscience.org/library/papers/33558705 | PubMed |
| 17 | 27257215 | Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. | Genes Dev | 2016 | https://conductscience.org/library/papers/27257215 | PubMed |
| 18 | 37067993 | TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. | Anticancer Drugs | 2023 | https://conductscience.org/library/papers/37067993 | PubMed |
| 19 | 22133676 | Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. | Biochem Biophys Res Commun | 2011 | https://conductscience.org/library/papers/22133676 | PubMed |
| 20 | 31665047 | JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31665047 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42903410 | Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903410 | PubMed |
| 42888460 | Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies. | Biomark Res | 2026 | https://conductscience.org/library/papers/42888460 | PubMed |
| 42839081 | Context matters for drug targeting. | Nat Chem Biol | 2026 | https://conductscience.org/library/papers/42839081 | PubMed |
| 42783444 | Therapeutic Vulnerabilities of the Key Genetic Drivers in Leiomyosarcoma. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42783444 | PubMed |
| 42449712 | Overcoming Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma (HNSCC): The Role of Histone Methyltransferase and Demethylase Inhibitors. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449712 | PubMed |
| 42325777 | KDM4D enhances radiosensitivity in esophageal squamous cell carcinoma through the SRBD1/RPL11/c-Myc/WIP1/CHK1 axis. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42325777 | PubMed |
| 41857315 | The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41857315 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40580997
GET https://conductscience.org/api/papers/v1/40580997/references?page=2